English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
 
 
DownloadE-Mail
  B cells and antibodies in multiple sclerosis pathogenesis and therapy

Krumbholz, M., Derfuss, T., Hohlfeld, R., & Meinl, E. (2012). B cells and antibodies in multiple sclerosis pathogenesis and therapy. Nature Reviews Neurology, 8(11), 613-623. doi:10.1038/nrneurol.2012.203.

Item is

Files

show Files

Locators

show

Creators

show
hide
 Creators:
Krumbholz, Markus1, Author           
Derfuss, Tobias, Author           
Hohlfeld, Reinhard1, Author           
Meinl, Edgar1, Author           
Affiliations:
1Department: Neuroimmunology / Wekerle, MPI of Neurobiology, Max Planck Society, ou_1113547              

Content

show
hide
Free keywords: CENTRAL-NERVOUS-SYSTEM; RITUXIMAB-TREATED PATIENTS; AUTOREACTIVE PLASMA-CELLS; BLOOD MONONUCLEAR-CELLS; CEREBROSPINAL-FLUID; NEUROMYELITIS-OPTICA; RHEUMATOID-ARTHRITIS; LUPUS-ERYTHEMATOSUS; CORTICAL DEMYELINATION; DISEASE PROGRESSION
 Abstract: B cells and antibodies account for the most prominent immunodiagnostic feature in patients with multiple sclerosis (MS), namely oligoclonal bands. Furthermore, evidence is accumulating that B cells and antibodies contribute to MS pathogenesis in at least a subset of patients. The CNS provides a B-cell-fostering environment that includes B-cell trophic factors such as BAFF (B-cell-activating factor of the TNF family), APRIL (a proliferation-inducing ligand), and the plasma-cell survival factor CXCL12. Owing to this environment, the CNS of patients with MS is not only the target of the immunopathological process, but also becomes the site of local antibody production. B cells can increase or dampen CNS inflammation, but their proinflammatory effects seem to be more prominent in most patients, as B-cell depletion is a promising therapeutic strategy. Other therapies not primarily designed to target B cells have numerous effects on the B-cell compartment. This Review summarizes key features of B-cell biology, the role of B cells and antibodies in CNS inflammation, and current attempts to identify the targets of pathogenic antibodies in MS. We also review the effects of approved and investigational interventions-including CD20-depleting antibodies, BAFF/APRIL-depleting agents, alemtuzumab, natalizumab, FTY720, IFN-beta, glatiramer acetate, steroids and plasma exchange-on B-cell immunology.

Details

show
hide
Language(s): eng - English
 Dates: 2012-11
 Publication Status: Published in print
 Pages: 11
 Publishing info: -
 Table of Contents: -
 Rev. Type: Peer
 Identifiers: ISI: 000310774100007
DOI: 10.1038/nrneurol.2012.203
 Degree: -

Event

show

Legal Case

show

Project information

show

Source 1

show
hide
Title: Nature Reviews Neurology
Source Genre: Journal
 Creator(s):
Affiliations:
Publ. Info: New York, NY, USA : Nature Publ. Group
Pages: - Volume / Issue: 8 (11) Sequence Number: - Start / End Page: 613 - 623 Identifier: ISSN: 1759-4758
CoNE: https://pure.mpg.de/cone/journals/resource/1759-4758